Mega Genomics Limited (6667.HK) HKSE

7.20

-0.05(-0.69%)

Updated at March 31 03:45PM

Currency In HKD

Mega Genomics Limited

Address

401 Health Work

Beijing,

China

Phone

86 40 0008 0280

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

214

First IPO Date

June 22, 2022

Key Executives

NameTitlePayYear Born
Ms. Jing JiangChief Financial Officer & Executive Director660,0551981
Ms. Lin LinExecutive Chairman1.73M1975
Dr. Rong YuExecutive Director & Honorary Co-Chairperson01971
Mr. Cong LiHead of Information Technology01984
Yong ZhaiCo-owner0N/A
Mr. Ka Chi NgCompany Secretary01977

Description

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.